Education
About Us
Working with TipRanks
Follow Us
Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
ACTU Stock Chart & Stats
$4.97
-$0.11(-1.36%)
At close: 4:00 PM EST
$4.97
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$4.96 - $11.99
Previous CloseN/A
Volume10.16K
Average Volume (3M)91.29K
Market Cap
$126.68M
Enterprise Value$93.25M
Total Cash (Recent Filing)$16.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding23,243,328
10 Day Avg. Volume100,190
30 Day Avg. Volume91,290
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.49K
Price to Sales (P/S)0.00
P/FCF Ratio-7.11
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$22.50Price Target Upside352.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyElraglusib combined with standard chemotherapy produced a meaningful improvement in overall survival versus chemotherapy alone in a randomized Phase 2 study, indicating strong clinical activity in metastatic pancreatic cancer.
Durability Of BenefitThe combination therapy demonstrated greater durability with higher longer-term survival rates compared with chemotherapy alone, supporting sustained patient benefit beyond initial responses.
Pediatric DevelopmentClinical responses, including complete responses, were observed in pediatric patients with Ewing sarcoma and neuroblastoma, supporting plans to expand development into pediatric Phase 2 trials.
Bears Say
Regulatory PathwayThe FDA did not grant Breakthrough Therapy Designation for elraglusib in first-line metastatic pancreatic cancer, representing a regulatory setback that may slow an expedited review pathway and affect market expectations.
Safety ProfileThe elraglusib arm had a notably higher rate of severe neutropenia, creating a tolerability concern that could complicate dosing, supportive care needs, and trial enrollment.
Actuate Therapeutics, Inc. News
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $4.96 and its highest was $11.99 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Actuate Therapeutics, Inc.’s market cap is $126.68M.
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 23,243,328 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actuate Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.50 (352.72% Upside)
$22.50 (352.72% Upside)
Blogger Sentiment
Bullish
ACTU Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
302.63%
Trailing 12-Months
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
ACTU Stock 12 Month Forecast
Average Price Target
$22.50
▲(352.72% Upside)
Technical Analysis
Agenus
―
Black Diamond Therapeutics
―
Nkarta
―
C4 Therapeutics
―
Kyverna Therapeutics, Inc.
―